<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80610">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01912547</url>
  </required_header>
  <id_info>
    <org_study_id>2013P000653</org_study_id>
    <nct_id>NCT01912547</nct_id>
  </id_info>
  <brief_title>Thromboelastography During Surgery for Malignant Pleural Mesothelioma</brief_title>
  <official_title>Thromboelastography During Surgery for Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgery for malignant pleural mesothelioma is complex and prolonged, and may involve
      significant blood loss with considerable blood and product transfusion. Thromboelastography
      (TEG) is a global assay of coagulation that uses whole blood to produce a tracing that
      records kinetic changes in clot formation. This study aims provide a better understanding of
      the coagulation profile of these patients, and will form the basis of a TEG-based
      transfusion algorithm for future surgeries for mesothelioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thromboelastography can provide more in-depth and quicker analysis of the complex
      coagulation processes during surgery
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Coagulation profile during extrapleural pneumonectomy or pleurectomy</measure>
    <time_frame>Surgical period (4-6 hours)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reaction time, alpha angle, maximum amplitude and clot lysis from thromboelastography give a better picture of coagulation at different phases of surgery</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coagulopathy</condition>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Blood draw for TEG analysis</arm_group_label>
    <description>TEG analysis of blood from patients at different points in time</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw for TEG analysis</intervention_name>
    <description>Blood drawn for TEG analysis</description>
    <arm_group_label>Blood draw for TEG analysis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients undergoing surgery for malignant pleural mesothelioma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male or female patients undergoing elective surgery for malignant pleural
             mesothelioma

        Exclusion Criteria:

          -  Unwilling or unable to provide consent

          -  History of bleeding disorder

          -  On medications that may affect hemostasis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ju-Mei Ng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BWH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ju-Mei Ng, MD</last_name>
      <phone>617-732-8219</phone>
      <email>jng1@partners.org</email>
    </contact>
    <investigator>
      <last_name>Ju-Mei Ng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 29, 2013</lastchanged_date>
  <firstreceived_date>July 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Ju-Mei Ng</investigator_full_name>
    <investigator_title>Instructor of Anaesthesia</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
